Advocate Group’s AstraZeneca AZN Stock Holding History

Advocate Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.06M	Sell	5,592 -325	-5%	-$61.1K	0.16%	84
2026 Q1	$1.17M	Sell	5,917 -194	-3%	-$37.4K	0.18%	82
2025 Q4	$1.12M	Sell	6,111 -155	-2%	-$27.2K	0.18%	81
2025 Q3	$961K	Sell	6,266 -16	-0.3%	-$2.42K	0.16%	80
2025 Q2	$878K	Sell	6,282 -61	-1%	-$8.55K	0.16%	82
2025 Q1	$932K	Hold	6,343	–	–	0.17%	80
2024 Q4	$831K	Sell	6,343 -3	-0%	-$420	0.16%	79
2024 Q3	$989K	Sell	6,346 -13	-0.2%	-$2.1K	0.18%	80
2024 Q2	$992K	Hold	6,359	–	–	0.2%	79
2024 Q1	$862K	Sell	6,359 -121	-2%	-$16K	0.17%	82
2023 Q4	$873K	Sell	6,480 -503	-7%	-$65.4K	0.19%	81
2023 Q3	$946K	Sell	6,983 -240	-3%	-$32.8K	0.22%	80
2023 Q2	$1.03M	Sell	7,223 -244	-3%	-$35.9K	0.23%	78
2023 Q1	$1.04M	Sell	7,467 -555	-7%	-$74.7K	0.23%	75
2022 Q4	$1.09M	Sell	8,022 -600	-7%	-$75.2K	0.23%	74
2022 Q3	$946K	Sell	8,622 -130	-1%	-$16.5K	0.23%	72
2022 Q2	$1.16M	Buy	+8,752	New	+$1.15M	0.27%	70

Other funds holding AZN

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

CDDEC

Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

BTCPP

Border to Coast Pensions Partnership Leeds, United Kingdom $6.78B AUM 31.6% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

ISS

Intesa Sanpaolo SpA. Turin, Italy $2.92B AUM

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Advocate Group's AZN Position: Q2 2026 in Review

Advocate Group reduced its AstraZeneca (AZN) stake by 5.5% in Q2 2026, selling an estimated $61.1K and leaving 5,592 shares worth $1.06M. The position accounts for 0.16% of the portfolio, ranked #84.

Advocate Group first reported a position in AZN in Q2 2022 and has held it in 17 quarters since. The position peaked at $1.17M in Q1 2026. 655 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Advocate Group held 5,592 shares of AstraZeneca worth $1.06M as of Q2 2026.
Advocate Group sold 325 AstraZeneca shares in Q2 2026, an estimated $61.1K.
AstraZeneca made up 0.16% of Advocate Group's portfolio in Q2 2026, its #84 holding.
Advocate Group first reported a position in AstraZeneca in Q2 2022 and has held it in 17 quarters since.
Advocate Group's AstraZeneca position peaked at $1.17M in Q1 2026.
655 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Advocate Group's 13F filing for Q2 2026, filed 17 Jul 2026.